AVZO-021 + palbociclib + fulvestrant

This is a **combination therapy** consisting of **AVZO-021** (a selective and potent cyclin-dependent kinase 2 [CDK2] inhibitor), **palbociclib** (a CDK4/6 inhibitor marketed as Ibrance), and **fulvestrant** (an estrogen receptor antagonist marketed as Faslodex). AVZO-021 is an investigational oral small molecule in early-phase clinical trials for advanced solid tumors, with a primary focus on hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer. Palbociclib inhibits CDK4/6, interrupting cell cycle progression. Fulvestrant is a selective estrogen receptor degrader (SERD) that antagonizes and degrades the estrogen receptor, blocking hormonal (estrogen-driven) tumor growth. The combination targets multiple key drivers of tumor proliferation: cell cycle kinases and estrogen signaling pathways.

Other names

palbociclibfulvestrant